ReviewPaediatric drugs2007
Pediatric overactive bladder syndrome: pathophysiology and management.
Review in Paediatric drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Long-term prospective evaluation of an inpatient voiding reeducation program for lower urinary tract conditions in children.International urology and nephrology · 2013Trial
- Extended-course transcutaneous tibial nerve stimulation for pediatric overactive bladder: a 6-Month prospective single-arm study.World journal of urology · 2026Article
- Updates of Overactive Bladder in Pediatrics.International neurourology journal · 2023Article
- Problems with enuresis management-A personal view.Frontiers in pediatrics · 2022Review
- Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.International journal of environmental research and public health · 2021Article
- Pharmacotherapy for Pediatric Neurogenic Bladder.Paediatric drugs · 2017Review
- Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.Cellular and molecular neurobiology · 2012Article
- Evaluation of autonomic function in children and adolescents with overactive bladder.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- Anticholinergic use in children: Persistence and patterns of therapy.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Flowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study.Sage open pediatricsArticle
- Do uroflowmetry and post - void residual urine tests necessary in children with primary nocturnal enuresis?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detrusor overactivity, also known as the overactive bladder syndrome (OAB), urge syndrome, hyperactive bladder syndrome, persistent infantile bladder, and detrusor hypertonia, is the most common voiding dysfunction in children. Until recently, the concepts that had been used to dictate the management of this problem in children were based on the foundation that this was a primary bladder problem and or a delay in maturation in the nervous system of children. The expectation that children would outgrow their problems led many pediatric urologists and other practitioners to tell the parents of these children 'that they would not be wetting themselves on their wedding day.' However, it has become apparent from recent studies in adult patients with voiding dysfunctions that they had symptoms present as children. Recent findings of associations between lower urinary tract symptoms and sexual dysfunction and between voiding dysfunctions and neuropsychiatric problems have opened up a new frontier into the possible mechanisms of OAB in children that would explain these problems, link them together, and explain the continued problems that adult patients face. These findings point to OAB as a symptom of a more centrally located dysfunction that affects multiple systems. The objective of this review was to evaluate the neuroanatomy and neurophysiology of voiding and neuropharmacologic effects. We considered not only the available research and clinical data within the urologic field but also outside the field so that these data could be combined to generate a unified theory that could possibly explain many of the associated symptoms that are commonly found in pediatric OAB. Treatment modalities that are currently available for managing OAB were also explored. Currently available data indicate that pediatric OAB and many pediatric voiding dysfunctions may be part of a more generalized problem that affects multiple systems: notably bowels, bladder, sexual and ejaculatory function, control of blood pressure, and even mood and behavior. We explain the relationship that the bowel has with pediatric OAB and also the link that other neuropsychiatric problems have with OAB. This article describes which drug may be best suited to treat OAB in children and what treatment modalities are available when first-line drugs fail. In conclusion, the movement away from a vesicocentric way of thinking to a more corticocentric mode of thinking along with new imaging modalities that can examine the brain as it works will be of great value in determining future treatments of OAB. Medications generated from these evidence-based studies will hopefully treat the underlying disease process and not just the symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.